Globalworld globe
United Kingdom
North America
Europe
  • facebook
  • linkedin
Medical Developments International
  • Home
  • Products
    • Asthma & COPD
    • Penthrox
    • Medical Devices
    • Veterinary
  • About
    • Distributor Information
    • Careers
    • Associations
  • Investors/Media
    • Financial Reports
    • Board of Directors/Management
    • Corporate Governance
    • Media Centre
    • Diversity Policy
    • Share Trading Policy
  • Healthcare Professionals
  • Contact

News

Green Whistle gets the Green Light – FDA clears US Penthrox clinical trial

Mar 2, 2022Mark EdwardsNews

2 March 2022

ASX ANNOUNCEMENT

Green Whistle gets the Green Light – FDA clears US Penthrox clinical trial

Medical Developments International Ltd (ASX: MVP) announces that the US Food and Drug Administration (FDA) has unconditionally lifted the agency’s clinical hold on Penthrox.  This means that MVP can immediately begin preparing for its Phase III US clinical trial.  As anticipated, the trial will be conducted on a targeted trauma and associated pain patient group.  We expect that the 2-year trial will commence recruitment in late 2022.

For further details please click on the following for the full announcement – ASX Announcement – Green Whistle gets the Green Light

 

Contact Us

for information on our range of products

Find a distributor

in our global network

Investors

invest in a company with
innovative foresight

News

  • Green Whistle gets the Green Light – FDA clears US Penthrox clinical trial

    2 March 2022 ASX ANNOUNCE...

  • MVP FY22 Half Year Results Investor Presentation

    25 February 2022 ASX anno...

  • MVP FY22 Half Year Report and Accounts

    24 February 2022 ASX Anno...

Healthcare Professional Registration

Login to access healthcare professional resources



Remember Me

Forgot password? | Register

Medical Developments International

Address:
4 Caribbean Drive, Scoresby,
Victoria, 3179
Australia
Phone: +61 3 9547 1888
Email: [email protected]
ABN: 14 106 340 667
For Medical Enquiries:

Phone: 1800 PENTHROX (1800 736 847)
Email: [email protected]

Email Newsletter